Abstract:Abstract Background Urine organic acids (UOA) analysis is an essential investigation for inborn errors of metabolism (IEMs). The vast majority of methods use gas chromatography mass spectrometry (GC-MS) and are only qualitative. Gas chromatography tandem mass spectrometry (GC-MS/MS) offers greater sensitivity and selectivity, and enables the combination of qualitative screening with quantitative analysis. We describe the development and preliminary validation results of a quantitative GC-MS/MS method. Methods Urine creatinine concentrations were measured (CobasPro, Roche Diagnostics) and normalized to 1.25 mmol/L. After internal standard addition, each urine specimen, calibration standard and QC were incubated with a hydroxylamine solution followed by a liquid-liquid extraction. Further sample concentration permitted the isolated UOA to be derivatized using N,O-bis(trimethylsilyl)trifluoroacetamine (BSTFA) with 1% chlorotrimethylsilane (TMCS) prior to injection. GC-MS/MS analysis was performed using a GC-MS-TQ8050 triple quadrupole system (Shimadzu) with a 30 m DB-5MS (Agilent J&W) capillary column (0.25 mm, ID of 0.25 μm). Split injection mode was deployed with an initial column temperature of 70°C. The mass spectrometer was operated in electron ionization (EI) and multiple reaction monitoring (MRM) modes. The linear concentration ranges of the targeted metabolites within the devised GC-MS/MS protocol were determined. Results The optimal temperature gradient for high-resolution UOA separations was derived and their respective retention times determined. MS/MS detection parameters were optimized to permit the identification of precursor and production ions for all (N = 38) derivatized UOA. Total analysis time was 33.8 min per injection. The achieved linear concentration ranges for each metabolite was respectively determined. Linear concentration ranges and correlation coefficients of representative UOA: 3-hydroxyisovaleric acid (range = 9 to 708 μmol/L, R2 = 0.9874); lactic acid (range = 15 to 751 μmol/L, R2 = 0.9936); 3-hydroxybutyric acid (range = 15 to 751 μmol/L, R2 = 0.9991); and 2-methyl-3-hydroxybutyric acid (range = 10 to 501 μmol/L, R2 = 0.9996). The correlation coefficients for all remaining UOA ranged from R2 = 0.9458 (4-hydroxyphenylpyruvic acid) to R2 = 0.9998 (3-methylglutanoic acid and ethylmalonic acid). Conclusion The devised GC-MS/MS protocol permits the unbiased identification and quantification of UOA used to investigate IEMs. The linear concentration ranges for all analytes were determined and are appropriate for monitoring these markers of inherited enzyme deficiencies. The analytical performance of this UOA GC-MS/MS method must be further validated and its diagnostic performance for selected IEMs characterized.

GC–MS urinary metabolomics analysis of inherited metabolic diseases and stable metabolic biomarker screening by a comprehensive chemometric method

Robust classification and biomarker discovery of inherited metabolic diseases using GC-MS urinary metabolomics analysis combined with chemometrics

Simultaneous Detection of Multiple Inherited Metabolic Diseases Using GC-MS Urinary Metabolomics by Chemometrics Multi-Class Classification Strategies.

Detection of Inborn Errors of Metabolism Utilizing GC-MS Urinary Metabolomics Coupled with a Modified Orthogonal Partial Least Squares Discriminant Analysis

Screening for Inherited Metabolic Diseases Using Gas Chromatography-Tandem Mass Spectrometry (Gc-Ms/ms) in Sichuan, China

Current Problems and Prospect on Tandem Mass Spectrometry Based Newborn Inherited Metabolic Diseases Screening

Wide metabolite coverage LC-MS/MS assay for the diagnosis of inherited metabolic disorders in urine

Using random forest to detect multiple inherited metabolic diseases simultaneously based on GC-MS urinary metabolomics

Efficient Mass Spectrometric Characterization and Classification of Methylmalonic Aciduria Subtypes Through Urinary and Blood Metabolic Profiles Fusion

[Combined Use of Tandem Mass Spectrometry with Urine Gas Chromatography/mass Spectrometry is Useful for Diagnosis of Inborn Errors of Metabolism in Children].

Result of a Pilot External Quality Assessment Scheme for Clinical Diagnosis of Inherited Metabolic Disorders in China.

The Determination of Organic Acids in Urine with Gas Chromatography-Mass Spectrometry and Its Application in Clinical Diagnosis

Application of gas chromatography-mass spectrometry analysis in the screening and diagnosis of organic acidurias

Untargeted Metabolomic Analysis for the Clinical Screening of Inborn Errors of Metabolism

B-201 Development of a Quantitative Gas Chromatography Tandem Mass Spectrometry Method for Metabolic Profiling of Urine Organic Acids

Detection of urine metabolites in patients with inherited metabolic diseases by nuclear magnetic resonance spectroscopy

Integration of Machine Learning Techniques as Auxiliary Diagnosis of Inherited Metabolic Disorders - Promising Experience with Newborn Screening Data.

Metabolomic Profiling of Human Urine as a Screen for Multiple Inborn Errors of Metabolism.

Coupling bootstrap with synergy self-organizing map-based orthogonal partial least squares discriminant analysis: Stable metabolic biomarker selection for inherited metabolic diseases

Selective Screening of Inborn Errors of Metabolism by Urease Pretreatment-Gas Ch Romatography-Mass Spectrometry:Pilot Study of 327 Patients at High Risk

Combined Application of NMR- and GC-MS-Based Metabonomics Yields a Superior Urinary Biomarker Panel for Bipolar Disorder